Exousia Pro, Inc. (OTCID:MAJI), a clinical-stage biotechnology company focused on proprietary exosome-based delivery systems, is excited to announce that it has executed a Letter of Intent to acquire a high-growth, established telehealth organization. Once acquired the Telehealth Platform will operate under Exousia Pro’s newly-formed subsidiary, Exousia Health, Inc. Exousia Health immediately gains control of a significant, established contract that designates the platform as the exclusive supplier of Testosterone across a robust network of 1,900 clinics.
Read the full article: Exousia Pro, Inc. Announces Executed LOI for Strategic Acquisition of High-Revenue Telehealth Platform //
Source: https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/exousia-pro-inc.-announces-executed-loi-for-strategic-acquisition-of-1116791